Contact
Paul England

Paul England, DPhil

Senior professional support lawyer

Read More
Contact
Paul England

Paul England, DPhil

Senior professional support lawyer

Read More

30 September 2020

Paul England discusses IP and pharma changes of the past decade, for Intellectual Property Magazine

Just a decade ago, during the financial crisis, the life sciences sector, dominated by small-molecule pharmaceuticals, was being squeezed.

On the one hand, pharma was finding it harder to identify small-molecule targets and match them with candidate drugs. On the other, it was meeting the challenge of generic competition to the ‘blockbuster’ drugs that had driven the market in the previous decade.

Paul outlines the recent changes in the life sciences sector, including the advance of technology and the implication for patents.

Read the full version originally published in the October edition of Intellectual Property Magazine (subscription required).

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

DNA helix
Life sciences & healthcare

Paul England writes on COVID-19 drug supply and patent system for Manufacturing Chemist

6 August 2020

by Paul England, DPhil

Click here to find out more